Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Stanley S. Schwartz, Paul S. Jellinger & Mary E. Herman. (2016) Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy’s safety profile. Postgraduate Medicine 128:6, pages 609-619.
Read now
Read now
Biju Jose, Abd A Tahrani, Milan K Piya & Anthony H Barnett. (2010) Exenatide once weekly: clinical outcomes and patient satisfaction. Patient Preference and Adherence 4, pages 313-324.
Read now
Read now
Steven V Edelman, Brock E Schroeder & Juan P Frias. (2007) Pramlintide acetate in the treatment of Type 2 and Type 1 diabetes mellitus. Expert Review of Endocrinology & Metabolism 2:1, pages 9-18.
Read now
Read now
Articles from other publishers (16)
Anju Das, K. M. Geetha & Iswar Hazarika. (2019) Contemporary Updates on the Physiology of Glucagon like Peptide-1 and Its Agonist to Treat Type 2 Diabetes Mellitus. International Journal of Peptide Research and Therapeutics 26:3, pages 1211-1221.
Crossref
Crossref
Dilip Sharma, Suril Verma, Shivani Vaidya, Kiran Kalia & Vinod Tiwari. (2018) Recent updates on GLP-1 agonists: Current advancements & challenges. Biomedicine & Pharmacotherapy 108, pages 952-962.
Crossref
Crossref
Bin ZhuNian Gong, Hui Fan, Chong-Sheng Peng, Xiu-Juan Ding, Yi Jiang & Yong-Xiang Wang. (2014)
Lamiophlomis rotata
, an Orally Available Tibetan Herbal Painkiller, Specifically Reduces Pain Hypersensitivity States through the Activation of Spinal Glucagon-like Peptide-1 Receptors
. Anesthesiology 121:4, pages 835-851.
Crossref
Crossref
Nian Gong, Hui Fan, Ai-Niu Ma, Qi Xiao & Yong-Xiang Wang. (2014) Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors. Neuropharmacology 84, pages 31-45.
Crossref
Crossref
Ralph A. DeFronzo, Curtis L. Triplitt, Muhammad Abdul-Ghani & Eugenio Cersosimo. (2014) Novel Agents for the Treatment of Type 2 Diabetes. Diabetes Spectrum 27:2, pages 100-112.
Crossref
Crossref
Jeff Unger. (2013) Rationale Use of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes. Current Diabetes Reports 13:5, pages 663-668.
Crossref
Crossref
John Armato, Ralph A. DeFronzo, Muhammad Abdul-Ghani & Ron Ruby. (2012) Successful Treatment of Prediabetes in Clinical Practice: Targeting Insulin Resistance and β-Cell Dysfunction. Endocrine Practice 18:3, pages 342-350.
Crossref
Crossref
Mauro Maurantonio, Stefano Ballestri, Maria Rosaria Odoardi, Amedeo Lonardo & Paola Loria. (2011) Treatment of Atherogenic Liver Based on the Pathogenesis of Nonalcoholic Fatty Liver Disease: A Novel Approach to Reduce Cardiovascular Risk?. Archives of Medical Research 42:5, pages 337-353.
Crossref
Crossref
E. CersosimoA. Gastaldelli, A. CerveraE. WajcbergA. SriwijilkamolM. FernandezP. ZuoR. Petz, C. TriplittN. MusiR. A. DeFronzo. (2011) Effect of Exenatide on Splanchnic and Peripheral Glucose Metabolism in Type 2 Diabetic Subjects. The Journal of Clinical Endocrinology & Metabolism 96:6, pages 1763-1770.
Crossref
Crossref
Ralph A. DeFronzo & Muhammad Abdul-Ghani. (2011) Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention. Diabetes Care 34:Supplement_2, pages S202-S209.
Crossref
Crossref
Nian Gong, Ai‐Niu Ma, Li‐Jie Zhang, Xiao‐Su Luo, Yin‐Hui Zhang, Michael Xu & Yong‐Xiang Wang. (2011) Site‐specific PEGylation of exenatide analogues markedly improved their glucoregulatory activity. British Journal of Pharmacology 163:2, pages 399-412.
Crossref
Crossref
R. A. DeFronzo. (2010) Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 53:7, pages 1270-1287.
Crossref
Crossref
Ralph A. DeFronzo. (2010) Overview of Newer Agents: Where Treatment Is Going. The American Journal of Medicine 123:3, pages S38-S48.
Crossref
Crossref
Ralph A. DeFronzo. (2009) From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus. Diabetes 58:4, pages 773-795.
Crossref
Crossref
Antonio Cervera, Estela Wajcberg, Apiradee Sriwijitkamol, Marianella Fernandez, Pengou Zuo, Curtis Triplitt, Nicolas Musi, Ralph A. DeFronzo & Eugenio Cersosimo. (2008) Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. American Journal of Physiology-Endocrinology and Metabolism 294:5, pages E846-E852.
Crossref
Crossref
Dennis Kim, Leigh MacConell, Dongliang Zhuang, Prajakti A. Kothare, Michael Trautmann, Mark Fineman & Kristin Taylor. (2007) Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes. Diabetes Care 30:6, pages 1487-1493.
Crossref
Crossref